Navigation Links
MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Date:11/14/2011

GAITHERSBURG, Md., Nov. 14, 2011 /PRNewswire/ -- MedImmune today announced the winners of its 6th Annual Research Abstract Competition highlighting the work of the next generation of scientific leaders performing research in the areas of respiratory, inflammatory and autoimmune (RIA) disease. Graduate students and postdoctoral fellows were invited to submit abstracts about RIA research as part of a competition sponsored by MedImmune, the global biologics arm of AstraZeneca.

First prize of $2,000 was awarded to Philippe LeBlanc of Department of Medicine, McGill University, Montreal, Canada, for his research topic, Caspase-1 processes HMGB1 into an immunogenic peptide that signals through RAGE.

LeBlanc noted, "Thank you to all the friendly staff at MedImmune who organized this conference and provided an important opportunity for academia to interface with the private research sector. Many congratulations and thanks to the other participants for sharing their excellent work."

Second and third prizes of $1,000 and $500 were awarded respectively to Jillian Barlow, Laboratory of Molecular Biology, Medical Research Council, Cambridge, UK, and Xiangping Yang, Ph.D, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.

Launched in 2006, MedImmune's Annual Research Abstract Competition aims to engage emerging scientists in health and science education to cultivate a competitive environment that nurtures future research in key therapeutic areas. In 2009, following the success of the RIA abstract competition in the U.S., MedImmune introduced a similar effort in Europe to acknowledge advances in the field of oncology. Since its inception, the MedImmune Annual Research Competition has received more than 330 research abstracts from across the globe.

"We are continuously impressed with the quality of submissions put forth by these young scientists each year," said Bing Yao, Senior Vice President, R&D and RIA iMed Head. "As a company committed to innovation and scientific education, the Abstract Competition allows us to foster the growth of future scientists and recognize the emerging talent in the scientific community."

MedImmune selected ten finalists from the 80 abstract submissions received this year. Today, finalists presented their research to a panel of MedImmune judges at the company's headquarters in Gaithersburg, MD. The panel of six judges from MedImmune's RIA department then selected the winners. The evaluation of abstracts was based on the following criteria: scientific rationale, description of methodology, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall presentation.

About MedImmune

MedImmune, the global biologics arm for AstraZeneca PLC, has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. For more information, visit MedImmune's website at www.medimmune.com


'/>"/>
SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Immune Design Grants Adjuvant License to MedImmune
2. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
3. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
4. HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1)
5. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
6. MedImmune Announces Zook as President
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
9. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
10. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... ... , ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled ... bold new look is part of a transformation to increase awareness, appeal to new ... , It will also expand its service offering from its signature gourmet cooking classes ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):